Clemens Schmitt, MD of the Max Delbruck Center for Molecular Medicine, Berlin, Germany discusses the potential to use targeted therapy for diffuse large B-cell lymphoma (DLBCL) at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA. According to Prof. Schmitt, the outcome for DLBCL patients is good but there is room for improvement. He explains that some collegues intensify conventional chemotherapy or immunochemotherapy. However, there is room for targeted therapies and the questions is what to select as actionable target and whether or not to preselect patients for early clinical testing or to apply in risk groups with enhanced risk.
The potential of targeted therapy in DLBCL: open questions
